AR065373A1 - Proteinas de fusion de inmunoglobulina y metodos de elaboracion - Google Patents

Proteinas de fusion de inmunoglobulina y metodos de elaboracion

Info

Publication number
AR065373A1
AR065373A1 ARP080100659A ARP080100659A AR065373A1 AR 065373 A1 AR065373 A1 AR 065373A1 AR P080100659 A ARP080100659 A AR P080100659A AR P080100659 A ARP080100659 A AR P080100659A AR 065373 A1 AR065373 A1 AR 065373A1
Authority
AR
Argentina
Prior art keywords
immunoglobulin
protein
polypeptide
immunoglobulin polypeptide
fusion proteins
Prior art date
Application number
ARP080100659A
Other languages
English (en)
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of AR065373A1 publication Critical patent/AR065373A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se revelan proteínas de fusion de inmunoglobulina y métodos de elaboracion de dichas proteínas.La proteína de fusion puede incluir un polipéptido no inmunoglobulina unido a un polipéptido inmunoglobulina, el polipéptido, no inmunoglobulina puedaincluir una region. que reemplaza a una region bisagra Fc de inmunoglobulina, pero que permite el ensamble correcto de las cadenas de inmunoglobulina tambien un acido nucleico que codifica dicha proteina un receptor que comprende el acido nucleicoasi como una celula que expresa la proteina. Reivindicacion 1: Una proteína de fusion que comprende: (a) un polipéptido inmunogiobulina del cual se ha extraído la region bisagra; y (b) un polipéptido no inmunoglobulina que comprende una porcionininterrumpida de una proteína supergénica de inmunoglobulina, en donde la porcion ininterrumpida de la proteína supergénica de inmunoglobulina está compuésta de un primer dominio de polipéptido no inmunoglobulina directamente unido al extremo N-terminal de un primer conector entre dominios, y en donde el polipéptido inmunoglobulina está unido de manera operable al extremo C-terminal del primer conector entre dominios.
ARP080100659A 2007-02-15 2008-02-15 Proteinas de fusion de inmunoglobulina y metodos de elaboracion AR065373A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90154007P 2007-02-15 2007-02-15

Publications (1)

Publication Number Publication Date
AR065373A1 true AR065373A1 (es) 2009-06-03

Family

ID=39690682

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100659A AR065373A1 (es) 2007-02-15 2008-02-15 Proteinas de fusion de inmunoglobulina y metodos de elaboracion

Country Status (6)

Country Link
US (2) US20080199467A1 (es)
AR (1) AR065373A1 (es)
CL (1) CL2008000460A1 (es)
TW (1) TW200848071A (es)
UY (1) UY30925A1 (es)
WO (1) WO2008100470A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3192872A1 (en) 2003-08-26 2017-07-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
EP1776459A1 (en) * 2004-08-03 2007-04-25 Transtech Pharma, Inc. Rage fusion proteins and methods of use
NZ552128A (en) * 2004-08-03 2009-09-25 Transtech Pharma Inc Rage fusion proteins without Fc hinge region and methods of use
CA2634908C (en) * 2005-12-23 2015-05-19 Gcoder Systems Ab Positioning pattern
US20090004190A1 (en) * 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
US7981424B2 (en) 2006-05-05 2011-07-19 Transtech Pharma, Inc. RAGE fusion proteins, formulations, and methods of use thereof
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
ES2564634T3 (es) 2007-06-14 2016-03-28 Galactica Pharmaceuticals, Inc. Proteínas de fusión de RAGE
EP2250196B1 (en) 2008-01-31 2012-12-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Engineered constant domain molecule of an antibody
EP2421892A1 (en) 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
JP6216921B2 (ja) 2011-06-24 2017-11-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１抗トリプシン融合分子のための組成物、方法および使用
EP2802653A4 (en) 2012-01-10 2015-09-02 Univ Colorado Regents ALPHA-1 ANTITRYPSIN FUSION MOLECULE COMPOSITIONS, METHODS AND USES THEREOF
EP3442554A4 (en) * 2016-04-14 2019-12-04 Iconic Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
CA2210684C (en) * 1995-01-18 2008-01-15 Alteon Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
FI119756B (fi) * 1995-01-18 2009-03-13 Alteon Inc Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa
AU5386996A (en) * 1995-04-05 1996-10-23 Picower Institute For Medical Research, The Agents for binding to advanced glycosylation endproducts, an d methods of their use
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6380165B1 (en) * 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US20020102604A1 (en) * 1999-12-08 2002-08-01 Milne Edwards Jean-Baptiste Dumas Full-length human cDNAs encoding potentially secreted proteins
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
PT1117421E (pt) * 1998-10-05 2004-11-30 Pharmexa A S Novos metodos para vacinacao terapeutica
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
ATE378418T1 (de) * 1998-10-06 2007-11-15 Univ Columbia Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
US6197294B1 (en) * 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
JP2003507013A (ja) * 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのＲＡＧＥへの結合を阻害する方法及びその結果
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
ES2286117T3 (es) * 2000-04-14 2007-12-01 Niadyne Corporation Metodo para identificar reguladores dela formacion de proteina-age.
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6563015B1 (en) * 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
AU2001296959A1 (en) * 2000-10-02 2002-04-15 Reddy Us Therapeutics, Inc Methods and compositions for the treatment of inflammatory diseases
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US20050244849A1 (en) * 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
WO2002066978A2 (en) * 2000-12-29 2002-08-29 Reddy Us Therapeutics, Inc. Detection of compounds that modulate inflammatory responses
KR20040074587A (ko) * 2001-02-19 2004-08-25 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 인공 단백질
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
EP1575513A4 (en) * 2002-08-16 2007-04-04 Wyeth Corp COMPOSITIONS AND METHODS FOR TREATING RAGE-ASSOCIATED DISEASES
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
JP2007503469A (ja) * 2003-05-20 2007-02-22 トランス　テック　ファーマ，インコーポレイテッド アミロイド症およびそれに関連した疾患を改善するための作用物質としてのｒａｇｅアンタゴニスト
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
AU2004270207A1 (en) * 2003-09-05 2005-03-17 The Trustees Of Columbia University In The City Of New York RAGE-related methods and compositions for treating glomerular injury
US20070167360A1 (en) * 2003-10-31 2007-07-19 Yan Shi D Methods for treating multiple sclerosis
US7151400B2 (en) * 2004-07-13 2006-12-19 Taiwan Semiconductor Manufacturing Company, Ltd. Boost-biased level shifter
EP1771565B1 (en) * 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
EP1776459A1 (en) * 2004-08-03 2007-04-25 Transtech Pharma, Inc. Rage fusion proteins and methods of use
NZ552128A (en) * 2004-08-03 2009-09-25 Transtech Pharma Inc Rage fusion proteins without Fc hinge region and methods of use
JP2008537874A (ja) * 2004-09-27 2008-10-02 セントカー・インコーポレーテツド ｓＲＡＧＥミメティボディ、組成物、方法および使用
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
US20090004190A1 (en) * 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
US7981424B2 (en) * 2006-05-05 2011-07-19 Transtech Pharma, Inc. RAGE fusion proteins, formulations, and methods of use thereof
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making

Also Published As

Publication number Publication date
US20080199467A1 (en) 2008-08-21
WO2008100470A3 (en) 2008-12-24
TW200848071A (en) 2008-12-16
UY30925A1 (es) 2008-09-30
CL2008000460A1 (es) 2008-08-22
US20110110945A1 (en) 2011-05-12
WO2008100470A2 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
AR065373A1 (es) Proteinas de fusion de inmunoglobulina y metodos de elaboracion
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
AR060862A1 (es) Proteinas de fusion rage, formulaciones y metodos de uso de estas
PE20091405A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
PE20091931A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
DE602005026219D1 (de) Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
EA201100908A1 (ru) Расширенные растворимые полипептиды рн20 и их использование
WO2009091826A3 (en) Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
CR11282A (es) Proteinas enlazadas al antigeno de celula de cepa mcdonough de felino humanas
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
MX2008002101A (es) Fusiones de la proteina-1 quimiotactica de monocito.
PE20120415A1 (es) Anticuerpos anti-igf
ATE470454T1 (de) Multimere konstrukte
EA201491049A1 (ru) Противораковый слитый белок
DK1948789T3 (da) Fremgangsmåde til fremstilling af permanente, humane cellelinjer
MX2011009810A (es) Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor.
HK1128727A1 (en) Chimaeric fusion protein with superior chaperone and folding activities
SG10201807877TA (en) Hybrid immunoglobulin containing non-peptidyl linkage
CY1118782T1 (el) Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια
EA200800565A1 (ru) Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
DK2007885T3 (da) Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider
NO20063374L (no) Fremgangsmate for fremstilling av tumornekrosefaktor-proteinbindinger
EA200700944A1 (ru) Миметические антитела, связывающие меланокортиновый рецептор, композиции, способы и применение
WO2007055823A3 (en) Gpcr expressing cell lines and antibodies

Legal Events

Date Code Title Description
FB Suspension of granting procedure